RedHill Biopharma Ltd (RDHL)

[midastouch017]

RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA(R) for Acute Gastroenteritis


TEL-AVIV, Israel and RALEIGH, N.C., Jun 19, 2017 (GLOBE NEWSWIRE via COMTEX) --

RedHill Biopharma Ltd. RDHL, +3.60% (tel-aviv stock exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the Company will host a conference call to review the recently announced successful Phase III GUARD study top-line results with BEKINDA [(R) ] (RHB-102) [1] for acute gastroenteritis and gastritis.
RedHill announced last week that the Phase III GUARD study with BEKINDA(R) 24 mg successfully met its primary endpoint of efficacy in treatment of acute gastroenteritis, and that BEKINDA [(R)] was found to be safe and well tolerated in this indication.


The conference call and webcast call will be held on Wednesday June 21, 2017 at 8:00 a.m. EDT.

The conference call, including a slide presentation, will be broadcasted live and available for replay on the Company's website, http://ir.redhillbio.com/events.cfm, for 30 days. Please access the Company's website at least 15 minutes ahead of the conference call to register, download, and install any necessary audio software.

Participants who wish to ask questions during the event can do so by telephone. To participate in the conference call, please dial the following numbers 5-10 minutes prior to the start of the call: United States: [phone]; International: [phone]; and Israel: [phone]. The access code for the call is 1536634.

About BEKINDA [(R)] (RHB-102):
BEKINDA [(R)] is a proprietary, bimodal extended-release (24 hours) oral pill formulation of ondansetron, covered by several issued and pending patents. Successful top-line results from a Phase III clinical study of BEKINDA [(R)] 24 mg in the U.S. for acute gastroenteritis and gastritis (the GUARD study) were announced in June 2017. A Phase II study with BEKINDA [(R) ] 12 mg is ongoing in the U.S. for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), with patient enrollment completed and top-line results expected in September 2017.